185 related articles for article (PubMed ID: 36202605)
1. Use of multikinase inhibitors/lenvatinib in patients with high cardiovascular risk/vasculopathy and radioiodine refractory-differentiated thyroid cancer.
Jimenez-Fonseca P
Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):17-25. PubMed ID: 36202605
[TBL] [Abstract][Full Text] [Related]
2. Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer.
Herranz UA
Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):47-53. PubMed ID: 36202606
[TBL] [Abstract][Full Text] [Related]
3. Clinical use of lenvatinib in patients with previous renal and/or hepatic impairment and radioiodine-refractory differentiated thyroid cancer.
Martínez-Trufero J
Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):5-9. PubMed ID: 36202603
[TBL] [Abstract][Full Text] [Related]
4. Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine-refractory differentiated thyroid cancer.
Berciano-Guerrero MÁ
Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):40-46. PubMed ID: 36202609
[TBL] [Abstract][Full Text] [Related]
5. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
6. Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit.
Wirth LJ; Durante C; Topliss DJ; Winquist E; Robenshtok E; Iwasaki H; Luster M; Elisei R; Leboulleux S; Tahara M
Oncologist; 2022 Jul; 27(7):565-572. PubMed ID: 35482606
[TBL] [Abstract][Full Text] [Related]
7. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study.
Kim M; Jin M; Jeon MJ; Kim EY; Shin DY; Lim DJ; Kim BH; Kang HC; Kim WB; Shong YK; Kim HK; Kim WG
Thyroid; 2023 Jan; 33(1):91-99. PubMed ID: 35443825
[No Abstract] [Full Text] [Related]
9. Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.
Hewett Y; Ghimire S; Farooqi B; Shah BK
J Oncol Pharm Pract; 2018 Jan; 24(1):28-32. PubMed ID: 27856921
[TBL] [Abstract][Full Text] [Related]
10. Pre-therapeutic evaluation and practical management of cardiovascular and renal toxicities in patients with metastatic radioiodine-refractory thyroid cancer treated with lenvatinib.
Wassermann J; Bagnis CI; Leenhardt L; Ederhy S; Buffet C
Expert Opin Drug Saf; 2022 Nov; 21(11):1401-1410. PubMed ID: 36458701
[TBL] [Abstract][Full Text] [Related]
11. Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer.
Giani C; Valerio L; Bongiovanni A; Durante C; Grani G; Ibrahim T; Mariotti S; Massa M; Pani F; Pellegriti G; Porcelli T; Salvatore D; Tavarelli M; Torlontano M; Locati L; Molinaro E; Elisei R
Thyroid; 2021 Feb; 31(2):224-232. PubMed ID: 32907501
[No Abstract] [Full Text] [Related]
12. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
[No Abstract] [Full Text] [Related]
13. Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer.
Tahara M; Kiyota N; Hoff AO; Badiu C; Owonikoko TK; Dutcus CE; Suzuki T; Ren M; Wirth LJ
Eur J Cancer; 2021 Apr; 147():51-57. PubMed ID: 33611104
[TBL] [Abstract][Full Text] [Related]
14. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
Wilson L; Huang W; Chen L; Ting J; Cao V
Thyroid; 2017 Aug; 27(8):1043-1052. PubMed ID: 28486081
[TBL] [Abstract][Full Text] [Related]
15. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.
Tahara M; Brose MS; Wirth LJ; Suzuki T; Miyagishi H; Fujino K; Dutcus CE; Gianoukakis A
Eur J Cancer; 2019 Jan; 106():61-68. PubMed ID: 30471649
[TBL] [Abstract][Full Text] [Related]
16. [Lenvatinib in radioiodine refractory thyroid carcinomas].
de la Fouchardiere C
Bull Cancer; 2016 Nov; 103(11):905-910. PubMed ID: 27817859
[TBL] [Abstract][Full Text] [Related]
17. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer.
Cabanillas ME; Takahashi S
Semin Oncol; 2019 Feb; 46(1):57-64. PubMed ID: 30685073
[TBL] [Abstract][Full Text] [Related]
18. Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios.
Zafón C; Castelo B
Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):3-4. PubMed ID: 36202604
[TBL] [Abstract][Full Text] [Related]
19. Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature.
Ye X; Zhu Y; Cai J
J Cancer Res Ther; 2015 Oct; 11 Suppl 2():C185-90. PubMed ID: 26506873
[TBL] [Abstract][Full Text] [Related]
20. The experience of an Endocrinology Division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer.
Jerkovich F; García Falcone MG; Pitoia F
Endocrine; 2019 Jun; 64(3):632-638. PubMed ID: 30820748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
